Outlook Therapeutics(US:OTLK) Globenewswire·2025-12-26 22:00Core Viewpoint - Outlook Therapeutics, Inc. has granted stock options to new employees as part of their compensation package, indicating a strategic move to attract talent in the biopharmaceutical sector focused on retinal diseases [1][2]. Company Overview - Outlook Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), aimed at enhancing the standard of care for retinal diseases [3]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet age-related macular degeneration (wet AMD) [3]. - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK for the treatment of wet AMD [3]. Product Development - In the United States, ONS-5010/LYTENAVA™ is currently investigational, and if approved, it would be the first ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4].